Exelixis’ Cabometyx (cabozantinib) Recommended by the NCCN in its Clinical Practice Guidelines for advanced RCC despite of patient risk status

 Exelixis’ Cabometyx (cabozantinib) Recommended by the NCCN in its Clinical Practice Guidelines for advanced RCC despite of patient risk status

Exelixis’ Cabometyx (cabozantinib) Recommended by the NCCN in its Clinical Practice Guidelines for advanced RCC despite of patient risk status

Shots:

  • Guidelines for Kidney Cancer: CABOMETYX (TKi) is recommended for 1L RCC patients in the poor- and intermediate-risk groups (Category 2A), 1L treatment for favourable-risk patients (Category 2B), and for previously treated patients (Category 1)
  • The (Category 2A) guidelines are based on P-II CABOSUN trial (N=157) in (ratio 1:1) administering cabozantinib (60mg qw)/sunitinib (50mg qw,4 wks. with 2 wks. off) showing improved PFS results in trial
  • Additionally, FDA has accepted cabometyx’s sNDA for previously treated advanced HCC (Child-Pugh Class A only) with PDUFA date of 14 Jan, 2019

Click here to read full press release/ article | Ref: Exelixis | Image:  Glassdoor

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post